Skip to main content
LUTATHERA Is Believed to Work Differently From Most Other Cancer Treatments

LUTATHERA is the first and only approved radioligand therapy (also known as RLT) for GEP-NET, a medicine from a class of drugs called peptide receptor radionuclide therapy (also known as PRRT).

LUTATHERA is believed to work differently from other cancer medicines, with a 2-part approach that specifically targets and enters the cells that have somatostatin receptors, releasing energy in the form of radiation that damages them and nearby cells.

In other words, LUTATHERA is a “key” that connects with the “lock” (cells containing somatostatin receptors).

1. Attaches to Target Cells

Image of a cell and Lutathera

LUTATHERA is designed to contain a tumor-targeting part that attaches to cells with somatostatin receptors, including GEP-NET cancer cells.

Image of Lutathera binding to receptors

Once it finds these cells, LUTATHERA is designed to bind to somatostatin receptors located on the outside of the cells.

2. Enters Into Cells

Image of Lutathera entering the cell

After LUTATHERA binds to the somatostatin receptors, it is designed to enter into the cell.

Image of Lutathera delivering the radiation

Finally, LUTATHERA is designed to deliver the radiation that causes damage to the targeted cells with the somatostatin receptor and neighboring cells.

Key of the diagram colors

Important Safety Information

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop...

Approved Use


LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive...